| Ytd | -22.22% | |
| 1y | -60.14% |
| Open | 2.21 | Prev Close | 2.22 | Low | 2.20 | High | 2.35 | Mkt Cap | 5.08M |
| Vol | 97.88K | Avg Vol | 62.23K | EPS | -27.79 | P/E | -0.08 | Forward P/E | -0.39 |
| Beta | 0.99 | Short Ratio | 2.45 | Inst. Own | 1.49% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 2.33 | 200-d Avg | 4.00 | 1yr Est | 6.00 |
Interim safety and efficacy data to be reported in Q1VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE
Processa Pharmaceuticals' stock jumps after Phase 2 data show higher capecitabine exposure witho
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCo
On Thursday, 369 companies hit new 52-week lows.
During Thursday's session, 406 companies made new 52-week lows.
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report